2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
Ra Pharmaceuticals Announces Initiation of First-in-Human Clinical Trial of Novel Complement C5 Inhibitor

Read More

Ra Pharmaceuticals Announces $58.5M Series B Financing. Complement C5 Inhibitor Peptide Poised to Enter Clinical Evaluation for Paroxysmal Nocturnal Hemoglobinuria. Multi-target Collaboration with Merck Extended

Read More

  • Printer Friendly Version 
  • E-mail this page 
  • RSS 
  • E-mail Alerts 
  • View contacts 
  • Download Financial Tear Sheet